Berrueta Mabel, Ciapponi Agustín, Mazzoni Agustina, Ballivian Jamile, Bardach Ariel, Sambade Juan M, Brizuela Martin, Stegelman Katharina, Comandé Daniel, Parker Edward P K, Stergachis Andy, Xiong Xu, Munoz Flor M, Buekens Pierre M
Instituto de Efectividad Clínica y Sanitaria (IECS), Dr. Emilio Ravignani 2024 (C1414CPV), Buenos Aires, Argentina.
Instituto de Efectividad Clínica y Sanitaria (IECS-CONICET), Buenos Aires, Argentina.
Reprod Health. 2025 Apr 18;22(1):56. doi: 10.1186/s12978-025-02004-2.
Chikungunya virus significantly impacts public health, primarily affecting regions in Africa and the Americas (predominantly Latin America and the Caribbean). Despite the global spread of the virus and its clinical manifestations and complications in vulnerable populations such as children and pregnant persons, no widely available vaccine is currently available. With recent advancements in vaccine development, there is a need to systematically evaluate the emerging evidence on the safety, immunogenicity, and efficacy of chikungunya vaccine candidates. This protocol outlines a living systematic review designed to continuously assess the growing research on chikungunya vaccines, focusing on diverse populations, including children and pregnant persons. We aim to provide up-to-date evidence to inform public health decisions and vaccine recommendations as new data is available.
Our objective is to carry out a living systematic review and meta-analysis through biweekly searches in medical databases and clinical trial registries, aiming to identify relevant chikungunya vaccines studies on pregnant individuals, children, and adolescents. Pairs of reviewers will independently screen studies, extract data, and assess the risk of bias. Clinical trials, quasi-experimental studies, and observational studies, including case reports, will be considered for inclusion. Main outcomes will include the safety, efficacy, and effectiveness of chikungunya vaccines in pregnant individuals (including neonatal outcomes), as well as in children and adolescents. Reactogenicity and immunogenicity will be considered as secondary outcomes. Paired meta-analyses, incorporating predefined subgroup and sensitivity analyses, will be performed. Evidence certainty will be assessed using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach.
This living systematic review and meta-analysis will continuously assess the safety, immunogenicity, and effectiveness of chikungunya vaccines in pregnant persons, children, and adolescents. Given the significant disease burden and potential complications in these populations, synthesizing emerging evidence is crucial for guiding immunization policies and clinical recommendations. By maintaining an updated analysis, this review will provide timely insights for public health agencies, researchers, and clinicians involved in vaccine implementation and maternal-child health.
Two protocols were registered in the International Prospective Register of Systematic Reviews database, CRD42024514513 and CRD42024516754.
基孔肯雅病毒对公共卫生有重大影响,主要影响非洲和美洲地区(主要是拉丁美洲和加勒比地区)。尽管该病毒在全球传播,且在儿童和孕妇等弱势群体中出现了临床表现和并发症,但目前尚无广泛可用的疫苗。随着疫苗研发的最新进展,有必要系统地评估关于基孔肯雅候选疫苗的安全性、免疫原性和有效性的新证据。本方案概述了一项动态系统评价,旨在持续评估关于基孔肯雅疫苗的不断增加的研究,重点关注包括儿童和孕妇在内的不同人群。我们的目标是在有新数据时提供最新证据,为公共卫生决策和疫苗建议提供依据。
我们的目标是通过每两周在医学数据库和临床试验注册库中进行检索,开展一项动态系统评价和荟萃分析,旨在识别关于孕妇、儿童和青少年的相关基孔肯雅疫苗研究。评审人员将独立筛选研究、提取数据并评估偏倚风险。将考虑纳入临床试验、准实验研究和观察性研究,包括病例报告。主要结局将包括基孔肯雅疫苗在孕妇(包括新生儿结局)以及儿童和青少年中的安全性、有效性和效果。反应原性和免疫原性将被视为次要结局。将进行纳入预定义亚组和敏感性分析的配对荟萃分析。将使用推荐分级评估、制定和评价(GRADE)方法评估证据确定性。
这项动态系统评价和荟萃分析将持续评估基孔肯雅疫苗在孕妇、儿童和青少年中的安全性、免疫原性和有效性。鉴于这些人群中重大的疾病负担和潜在并发症,综合新出现的证据对于指导免疫政策和临床建议至关重要。通过保持最新分析,本评价将为参与疫苗实施和母婴健康的公共卫生机构、研究人员和临床医生提供及时的见解。
两项方案已在国际前瞻性系统评价注册数据库(CRD42024514513和CRD42024516754)中注册。